Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis

Lupus

Volumn 15, Issue 6, 2006, Pages 366-370

  Kasitanon, N ^a   Fine, D M ^a   Haas, M ^a   Magder, L S ^b   Petri, Michelle ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Hydroxychloroquine; Membranous lupus nephritis; Mycophenolate mofetil

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CONTROL; DRUG USE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PREDNISONE; PROGNOSIS; PROTEINURIA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33745849739     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203306lu2313oa     Document Type: Article

References (15)

1. Christiansen JV, Nielsen JP. Treatment of lupus erythematosus with mepacrine; results and relapses during a long observation. Br J Dermatol 1956; 68: 73-87.
2. Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975; 2: 323-330.
3. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
4. Fessler BJ, Alarcon GS, McGwin G Jr et al.; LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52: 1473-1480.
5. Tsakonas E, Joseph L, Esdaile JM et al.; The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998; 7: 80-85.
6. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23: 82-91.
7. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
8. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115: 407-17.
9. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
10. Weening JJ, D'agati VD, Schwartz MM et al. The Classifcation of Glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
11. Austin HA 3rd, Muenz LR, Joyce KM et al. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
12. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
13. Petri M, Barr SG, Buyon J et al. RIFLE: Responder Index for Lupus Erythematosus. Arthritis Rheum 2000; 43: S244 (abstract).
14. Mok CC, Ying KY, Lau CS et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004; 43: 269-276.
15. Petri M. Hydroxychloroquine prevents later damage in SLE. Arthritis Rheum 2001; 44: S280.